• Impact of vascular biology in treatment of cardiovascular disease
Section IV: Antithrombotic interventions in acute coronary syndromes
The VBWG Core Curriculum 2003 slide lecture compendium Impact of vascular biology in treatment of cardiovascular disease
, provides updates on new science and mechanisms of disease, plus implications of recent clinical trials.
Areas of focus:
The slides and accompanying notes in the 2002 VBWG core curriculum provided a broad overview of antithrombotic therapy. The 2003 program focuses on the interrelationship between antithrombotic therapy and catheterization in patients presenting with acute coronary syndromes (ACS). Another noteworthy feature of this year's program is a section on the adverse implications of diabetes in the patient with ACS.
A. Epidemiology Update
Download 03ACSA001.ppt (2 slides - 0.4MB)
B. Prothrombotic and antithrombotic pathways in the coronary vasculature
Download 03ACSB001.ppt (4 slides - 0.8MB)
C-1. Clinical trial updates: Percutaneous coronary intervention
Download 03ACSC001.ppt (7 slides - 1.3MB)
C-2. Clinical trial updates: Direct thrombin inhibitors
Download 03ACSC002.ppt (3 slides - 0.6MB)
C-3. Clinical trial updates: GP IIb/IIIa inhibitors
Download 03ACSC003.ppt (3 slides - 0.6MB)
C-4. Clinical trial updates: Low-molecular-weight heparin
Download 03ACSC004.ppt (13 slides - 2.8MB)
D. Impact of Diabetes in ACS
Download 03ACSD001.ppt (7 slides - 1.3MB)
Published by Medical Education Consultants, Inc. (MEDCON), on behalf of the University of Florida College of Medicine.
The editorial content of this program does not necessarily reflect the views or recommendations of the University of Florida
College of Medicine or AstraZeneca, Aventis Pharmaceuticals Inc, King Pharmaceuticals, Pfizer Inc, Wyeth Pharmaceuticals,
or the publisher. The reader is advised to consult the full prescribing information of each product prior to use.
This program was prepared and produced by Medical Education Consultants, Inc, Westport, Connecticut, on behalf of the
University of Florida College of Medicine through an unrestricted educational grant provided by AstraZeneca, Aventis
Pharmaceuticals Inc, King Pharmaceuticals, Pfizer Inc, and Wyeth Pharmaceuticals.
©2003 Medical Education Consultants, Inc. (MEDCON). All rights reserved.